These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

568 related items for PubMed ID: 24782109

  • 1. Successful management of thrombotic thrombocytopenic purpura in a Jehovah's Witness without plasma exchange.
    Chai W, Chaudhry A, Rabinowitz AP.
    J Clin Apher; 2015 Feb; 30(1):46-9. PubMed ID: 24782109
    [Abstract] [Full Text] [Related]

  • 2. Successful management of a Jehovah's Witness with thrombotic thrombocytopenic purpura unwilling to be treated with therapeutic plasma exchange.
    Dabak V, Kuriakose P, Raman S.
    J Clin Apher; 2007 Feb; 22(6):330-2. PubMed ID: 18080270
    [Abstract] [Full Text] [Related]

  • 3. Survival of a Jehovah's Witness with thrombotic thrombocytopenic purpura without using plasma: A case report and review of the literature.
    Baseri B, Vishwanathan S, Benasher D, Khazan M, Luhrs C, Tsai HM.
    J Clin Apher; 2019 Oct; 34(5):623-630. PubMed ID: 31116457
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic modalities in thrombotic thrombocytopenic purpura management among Jehovah's Witness patients: A review of reported cases.
    Tran MH.
    Transfus Apher Sci; 2023 Aug; 62(4):103706. PubMed ID: 36990894
    [Abstract] [Full Text] [Related]

  • 5. Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah's Witness.
    Martin MG, Whitlatch NL, Shah B, Arepally GM.
    Am J Hematol; 2007 Jul; 82(7):679-81. PubMed ID: 17266059
    [Abstract] [Full Text] [Related]

  • 6. Pegylated bovine carboxyhaemoglobin utilisation in a thrombotic thrombocytopenic purpura patient.
    Sam C, Desai P, Laber D, Patel A, Visweshwar N, Jaglal M.
    Transfus Med; 2017 Aug; 27(4):300-302. PubMed ID: 28401611
    [Abstract] [Full Text] [Related]

  • 7. Caplacizumab Without Plasma Exchange for Thrombotic Thrombocytopenic Purpura in a Jehovah's Witness.
    Spencer C, Abuhelwa Z, Beran A, Alsughayer A, Sheikh T, Oostra D, Assaly R, Hamouda DM.
    Am J Ther; 2017 Aug; 30(5):e502-e505. PubMed ID: 37713712
    [No Abstract] [Full Text] [Related]

  • 8. To treat or not to treat: a rare case of pseudo-thrombotic thrombocytopenic purpura in a Jehovah's Witness.
    Malla M, Seetharam M.
    Transfusion; 2016 Jan; 56(1):160-3. PubMed ID: 26363181
    [Abstract] [Full Text] [Related]

  • 9. Serial ADAMTS13 measurements during initial plasma exchange therapy guide decisions for management of unresponsive thrombotic thrombocytopenic purpura.
    van der Veen BS, Besseling R, Hoogendoorn M.
    Transfusion; 2015 Oct; 55(10):2511-5. PubMed ID: 26308736
    [Abstract] [Full Text] [Related]

  • 10. A case series of atypical presentations of thrombotic thrombocytopenic purpura.
    Imanirad I, Rajasekhar A, Zumberg M.
    J Clin Apher; 2012 Oct; 27(4):221-6. PubMed ID: 22467376
    [Abstract] [Full Text] [Related]

  • 11. [Successful treatment with rituximab in a patient with refractory thrombotic thrombocytopenic purpura refractory to plasma exchange].
    Koshino M, Kudou D, Okoshi Y, Obara N, Simizu S, Mukai HY, Suzukawa K, Hasegawa Y, Kojima H, Nagasawa T, Chiba S.
    Rinsho Ketsueki; 2010 Feb; 51(2):127-31. PubMed ID: 20379104
    [Abstract] [Full Text] [Related]

  • 12. [Successful delivery following treatment with plasma exchange in a female patient with thrombotic thrombocytopenic purpura].
    Takagi Y, Adachi Y, Tsujimura A, Tsushita K.
    Rinsho Ketsueki; 2012 Aug; 53(8):770-3. PubMed ID: 22975818
    [Abstract] [Full Text] [Related]

  • 13. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.
    Pandey S, Nakagawa M, Rosenbaum ER, Arnaoutakis K, Hutchins LF, Makhoul I, Milojkovic N, Cottler-Fox M.
    J Clin Apher; 2015 Feb; 30(1):50-4. PubMed ID: 25042026
    [Abstract] [Full Text] [Related]

  • 14. [Multi-facetted clinical presentation of thrombotic thrombocytopenic purpura].
    Niemann CU, Jurlander J, Daugaard G, Friis-Hansen L.
    Ugeskr Laeger; 2009 Jan 26; 171(5):340-2. PubMed ID: 19176177
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. COVID 19 infection associated with thrombotic thrombocytopenic purpura.
    Dhingra G, Maji M, Mandal S, Vaniyath S, Negi G, Nath UK.
    J Thromb Thrombolysis; 2021 Aug 26; 52(2):504-507. PubMed ID: 33904053
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura.
    Coppo P, Veyradier A.
    Presse Med; 2012 Mar 26; 41(3 Pt 2):e163-76. PubMed ID: 22265954
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.